| Literature DB >> 28835938 |
Sitthichai Iamsaard1,2, Wannisa Sukhorum1,3, Supatcharee Arun1, Nichapa Phunchago1, Nongnuch Uabundit1, Porntip Boonruangsri1, Malivalaya Namking1.
Abstract
BACKGROUND: Valproic acid (VPA), an anti-epileptic drug, can cause male subfertility. However, the degree to which testicular and epididymal histopathologies and androgen receptor (AR) expression are changed under VPA treatment has never been reported.Entities:
Keywords: Androgen receptor; Epididymis; Histopathology; Testis; Valproic acid
Year: 2017 PMID: 28835938 PMCID: PMC5555039
Source DB: PubMed Journal: Int J Reprod Biomed ISSN: 2476-3772
The body and male reproductive organ weights of rats treated with VPA for 10 consecutive days compared to the controls
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Cont-D1 | 254.65±4.67 | 1.36±0.07 | 0.23±0.02 | 0.42±0.05 | 0.54±0.03 | 0.09±0.01 | 0.17±0.02 |
| VPA-D1 | 249.99±5.41 | 1.36±0.02 | 0.25±0.03 | 0.38±0.02 | 0.57±0.02 | 0.10±0.01 | 0.16±0.01 |
| VPA-D2 | 245.06±6.77 | 1.24±0.05 | 0.25±0.02 | 0.42±0.08 | 0.51±0.05 | 0.10±0.01 | 0.17±0.04 |
| VPA-D3 | 246.04±13.03 | 1.29±0.05 | 0.26±0.02 | 0.44±0.08 | 0.53±0.03 | 0.11±0.01 | 0.18±0.03 |
| VPA-D4 | 247.19±11.73 | 1.29±0.10 | 0.28±0.03 | 0.47±0.07 | 0.49±0.02 | 0.11±0.01 | 0.18±0.02 |
| VPA-D5 | 252.06±19.15 | 1.19±0.10 | 0.26±0.03 | 0.45±0.12 | 0.47±0.01 | 0.10±0.01 | 0.18±0.04 |
| VPA-D6 | 255.64±16.07 | 1.17±0.14 | 0.27±0.03 | 0.45±0.4 | 0.46±0.03 | 0.11±0.01 | 0.18±0.04 |
| VPA-D7 | 257.16±15.16 | 1.16±0.16 | 0.27±0.02 | 0.55±0.06 | 0.43±0.06 | 0.11±0.02 | 0.21±0.02 |
| VPA-D8 | 245.63±10.15 | 1.16±1.17 | 0.30±0.02 | 0.53±0.11 | 0.43±0.04 | 0.12±0.01 | 0.22±0.04 |
| VPA-D9 | 256.60±14.45 | 1.16±0.04 | 0.32±0.02 | 0.56±0.13 | 0.46±0.01 | 0.13±0.01 | 0.22±0.04 |
| VPA-D10 | 272.11±8.86 | 1.14±0.09 | 0.32±0.01 | 0.66±0.06 | 0.42±0.01 | 0.12±0.00 | 0.24±0.02 |
| Cont-D10 | 303.76±9.01 | 1.64±0.08 | 0.37±0.02 | 1.15±0.22 | 0.54±0.04 | 0.12±0.00 | 0.38±0.06 |
D: day
VPA: valproic acid
Cont: control.
Significant differences (P<0.05), compared with the control-D10 group. Data are represented as means±SD (n=8 / each group)
Figure 1Comparative morphology of rat testes between the controls and VPA-treated groups (days 1-10)
Figure 2The sperm concentration of rats treated with VPA (500mg/kgBW) for consecutive 10 days compared to controls (days 1 - 10)
Figure 3Photomicrographs showing histology of testis stained by H&E of the control day1 (A), VPA treated days 1-10 (B-K), and control day 10 (L), respectively
Figure 4Photomicrographs showing histopathology of seminiferous tubules stained by H&E of VPA-treated day 6(A+B), 7(C+D), 8(E+F), 9(G+H), and 10(I+J), respectively
Figure 5Photomicrographs showing histopathology (H&E) of caput epididymis (A-C) and cauda epididymis (D) of VPA-treated day10
Figure 6Representative immuno-Western blotting of androgen receptor in testicular and epididymal protein lysate of control and VPA groups taken from experiment day 10 (n = 4). β-actin was used as internal control